Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of KOS-1584 in previously treated advanced non-small cell lung cancer
2007-006193-29Phase 2Completed
- Sponsor
- Kosan Biosciences
- Start
- Oct 2008
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KOS-1584 in non-small cell lung cancer (NSCLC), sponsored by Kosan Biosciences. Primary endpoint: Objective response rate. Started Oct 2008; status: completed.
02
Drugs
KOS-1584
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-006193-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006193-29.